Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1]
U. Bergstrom, C. Book, Y. Lindroth, L. Marsal, T. Saxne, L. Jacobsson.
Lower disease activity and disability in Swedish patients with rheumatoid arthritis in 1995 compared with 1978.
Scand J Rheumatol, 28 (1999), pp. 160-165
[2]
A. Finckh, H.K. Choi, F. Wolfe.
Progression of radiographic joint damage in different eras: trends towards milder disease in rheumatoid arthritis are attributable to improved treatment.
Ann Rheum Dis, 65 (2006), pp. 1192-1197
[3]
A. Balsa.
¿Cómo se evalúa una respuesta inadecuada en un paciente con arthritis reumatoide?.
Reumatol Clin, 3 (2007), pp. 38-44
[4]
X. Le Loët, J.M. Berthelot, A. Canagrel, B. Combe, M. De Bandt, B. Fautrel.
Clinical practice decisión tree for the choice of the first modifing antirheumatic drug for very early rheumatoid arthritis: a 2004 proposal of the French Society of Rheumatology.
Ann Rheum Dis, 65 (2006), pp. 45-50
[5]
C. Grigor, H. Capell, A. Stirling, A.D. McMahon, P. Lock, R. Wallance, et al.
Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial.
Lancet, 364 (2004), pp. 263-269
[6]
Y.P.M. Goekoop-Ruiterman, J.K. De Vries-Bouwstra, C.F. Allaart, D. Van Zeben, P.J.S.M. Kerstens, J.M.W. Hazes, et al.
Clinical and radiographic outcomes of four different treatment strategies in patiens with early rheumatoid arthritis (the BeSt study).
Arthritis Rheum, 52 (2005), pp. 3381-3390
[7]
H. Mäkinen, H. Kautiainen, P. Hannonen, T. Sokka.
Is DAS28 an appropiate tool to assess remission in rheumatoid arthritis?.
Ann Rheum Dis, 64 (2005), pp. 1410-1413
[8]
E.T.H. Molenaar, A.E. Voskuyl, H.J. Dinant, P.D. Bezemer, M. Boers, B.A.C. Dijkmans.
Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission.
Arthritis Rheum, 50 (2004), pp. 36-42
[9]
Rees JD, Pilcher J, Heron C, Kiely PD. A comparison of clinical vs ultrasound determined synovitis in rheumatoid arthritis utilizing grayscale, power Doppler and the intravenous microbubble contrast agent Sono-Vue(R). Rheumatology (Oxford). 2006 Aug 9 [Epub ahead of print].
[10]
M.C. Genovese, A.F. Kavanaugh, S.B. Cohen, P. Emery, E.H. Sasso, G.T. Spencer-Green.
The Relationship of radiographic progression to clinical response in patients with early rheumatoid arthritis treated with adalimumab (HUMIRA) plus methotrexate or methotrexate alone.
Arthritis Rheum, 52 (2005), pp. S451
[11]
K. Eberhardt, E. Fex.
Clinical course and remission rate in patients with early rheumatoid arthritis: relationship to outcome after 5 years.
Br J Rheumatol, 37 (1998), pp. 1324-1329
[12]
L. Gossec, M. Dougados, P. Goupille, A. Cantagrel, J. Sibilia, O. Meyer, et al.
Prognostic factors for remission in early rheumatoid arthritis: a multiparameter prospective study.
Ann Rheum Dis, 63 (2004), pp. 675-680
[13]
Vázquez I, Graell E, Moll C, Gratacos J, Gómez-Centeno A, Larrosa M, et al. Prognostic markers of remission in early rheumatoid arthritis after two years of DMARDs in a clinical setting. Clin Exp Rheumatol. 2006. En prensa.
[14]
E.W. St Clair, D.M.F.M. Van der Heijde, J.S. Smolen, R.N. Maini, J.M. Bathon, P. Emery, Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Group, et al.
Combination of infliximab and methotrexate therapy for early rheumatoid arthritis.
Arthritis Rheum, 50 (2004), pp. 3432-3443
[15]
P.L. Ramsay, F.C. Breedveld, M.H. Weisman, A.F. Kavanaugh, S.B. Cohen, K. Pavelka, The PREMIER Investigators. The PREMIER Study, et al.
A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.
Arthritis Rheum, 54 (2006), pp. 26-37
[16]
M.C. Genovese, J.M. Bathon, R.W. Martin, R.M. Fleischmann, J.R. Tesser, M.H. Schiff, et al.
Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes.
Arthritis Rheum, 46 (2002), pp. 1443-1450
[17]
J. Listing, A. Strangfeld, R. Rau, J. Kekow, E. Gromnica-Ihle, T. Klopsch, et al.
Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low-results from RABBIT, the German biologics register.
Arthritis Res Ther, 8 (2006), pp. R66
[18]
III Actualización del consenso de la Sociedad Española de Reumatología sobre la terapia biológica en la artritis reumatoide. Reumatol Clin. 2006; 2(supl):52-9.
[19]
J. Ledingham, C. Deighton.
Update on the British Society for Rheumatology guidelines for prescribing TNF-α blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001).
Rheumatology, 44 (2005), pp. 157-163
[20]
M.A. Quinn, P.G. Conaghan, P.J. O’Connor, Z. Karim, A. Greenstein, A. Brown, et al.
Very early treatment with infliximab in addition to methotrexate in early,poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal:results from a twelve-month randomized, double-blind, placebo-controlled trial.
Arthritis Rheum, 52 (2005), pp. 27-35
Copyright © 2007. Elsevier España S.L Barcelona
